Papers

Peer-reviewed International journal
2021

Factors associated with anti-SARS-CoV-2 IgG antibody production in patients convalescing from COVID-19.

Journal of Infection and Chemotherapy
  • Kutsuna S
  • Asai Y
  • Matsunaga A
  • Kinoshita N
  • Terada M
  • Miyazato Y
  • Nakamoto T
  • Suzuki T
  • Saito S
  • Endo M
  • Kanda K
  • Maeda K
  • Takasaki J
  • Hojo M
  • shizaka Y
  • Ohmagari N
  • Display all

Volume
27
Number
6
First page
808
Last page
813
Language
English
Publishing type
Research paper (scientific journal)
DOI
10.1016/j.jiac.2021.01.006

INTRODUCTION: Among patients with coronavirus disease 2019 (COVID-19), the factors that affect anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody production remain unclear. This study aimed to identify such factors among patients convalescing from COVID-19. METHODS: This study comprised patients who had been diagnosed with COVID-19 between January 1 and June 30, 2020 and gave consent for anti-SARS-CoV-2 spike protein antibody measurement using enzyme-linked immunosorbent assay during their acute and/or convalescent phases. Factors related to elevated antibody titers and the relationship between the days from disease onset and the development of antibody titers were assessed. RESULTS: A total of 84 participants enrolled in the study. Nineteen participants had antibody titers measured during the convalescent phase only, and 65 participants had antibody titers measured during the acute and convalescent phases. The antibody titers peaked in weeks 5 and 6. The stepwise multivariate log-normal analysis revealed that male sex (P = 0.04), diabetes mellitus (P = 0.03), and high C-reactive protein levels during the disease course (P < 0.001) were associated with elevated IgG antibodies. Glucocorticoid use was not associated with antibody titers. CONCLUSION: The study found that high values of maximum CRP levels during the acute phase, male sex, and diabetes mellitus were associated with elevated antibody titers. Antibody titers tended to be highest in the first 5 or 6 weeks after the onset of symptoms.

Link information
DOI
https://doi.org/10.1016/j.jiac.2021.01.006
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/33531292
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836855
ID information
  • DOI : 10.1016/j.jiac.2021.01.006
  • Pubmed ID : 33531292
  • Pubmed Central ID : PMC7836855

Export
BibTeX RIS